sy-5609
Generic: CDK7 Inhibitor SY-5609·Code: SY-5609
sy-5609: sourced relationships with 1 company · 1 clinical trial tracked.
sy-5609 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect sy-5609 to SYRS; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could sy-5609 → SYRS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Solid tumors and pancreatic cancerMetastatic Colorectal Cancer
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Syros Pharmaceuticals, Inc. (SYRS) Solid tumors and pancreatic cancer | Phase 1 |
Clinical Trial Registry Records (1)
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Primary endpoint: Objective Response Rate
InterventionalRandomizedopen542 targetStarted 2021-10Completion 2030-0850 sites · Australia, Canada, Denmark, Germany…Hoffmann-La Roche
Frequently asked questions
Which companies have sourced relationships with sy-5609?
sy-5609 has dated SEC/FDA relationship records for Syros Pharmaceuticals, Inc..
How many clinical trials involve sy-5609?
BioSniper tracks 1 clinical trial involving sy-5609.